Nebraska Passes Kratom Consumer Protection Act, Setting a State Standard for Kratom Regulation
GKC has been actively engaged with Nebraska lawmakers since early 2024, advocating for evidence-based standards that preserve access to natural kratom while shielding the public from dangerous synthetic products that falsely claim to be kratom.
LB 230 includes robust protections for consumers, such as prohibiting the marketing of kratom products to children, banning sales to individuals under 21 years old, and requiring product labeling that discourages use by pregnant or breastfeeding women.
'The Nebraska legislature should be commended for leading the way in creating common sense regulations for kratom, keeping it safe and accessible for consumers,' said Matthew Lowe, Executive Director of the Global Kratom Coalition. 'Nebraska lawmakers have created a model for other states to pursue by including provisions in the legislation with some real teeth.'
One of the most impactful provisions of the bill restricts the level of 7-hydroxymitragynine (7OH) in kratom products to no more than 2% of the total alkaloid composition. This critical safeguard eliminates the threat posed by highly concentrated 7OH synthetic products — commonly referred to as '7'— which have been proliferating across the country.
Unlike natural-leaf kratom, these synthetically altered products contain eight unknown compounds and levels of 7OH up to 100 times higher than naturally occurring kratom. These untested products lack scientific backing for claims of treating chronic pain and opioid use disorder.
Despite mounting scientific consensus and public health concern, groups like the Holistic Alternative Recovery Trust (HART) have actively sought to undermine the bill or strip out key consumer protections. HART continues to promote synthetic '7' products without offering credible data, directly contradicting the views of leading U.S. kratom researchers who assert that '7' products should not be considered kratom.
During a press event in October 2024, HART panelists advocated for regulating 7OH products as though they were natural kratom, making unapproved drug claims without FDA authorization.
'When organizations like HART are advocating for products that are unapproved drugs that have not gone through the FDA approval process,' said Lowe. 'Without FDA approval, selling those products is unlawful and puts consumers at risk.'
Since the introduction of LB 230 on January 14, 2025, GKC has worked closely with stakeholders to ensure the legislation balances access to safe, natural kratom with strong protections against dangerous synthetic alternatives.
'Our goal has always been to support legislation that empowers consumers to make informed choices and preserves access to responsibly manufactured kratom products,' said Lowe. 'With the passage of Nebraska's Kratom Consumer Protection Act, we've made a significant leap toward that vision.'
The Global Kratom Coalition thanks the Nebraska Legislature for standing up for consumer safety and urges other states to follow Nebraska's lead by adopting meaningful, science-based kratom regulation.
About Global Kratom Coalition
The Global Kratom Coalition is an alliance of kratom consumers, experts, and industry leaders dedicated to protecting access to kratom while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. For more information, visit https://globalkratomcoalition.org.
Media Contact
Patrick George
+1 916-202-1982
[email protected]
###
SOURCE: Global Kratom Coalition
Copyright 2025 EZ Newswire
https://app.eznewswire.com/news/nebraska-passes-kratom-consumer-protection-act-setting-a-state-standard-for-kratom-regulation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
By Jacob Gronholt-Pedersen COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks. Novo's shares rose as much as 5% at opening and were trading 3.5% higher by 0711 GMT. Three weeks ago, investors wiped $70 billion off its market value, after Novo - which became Europe's most valuable listed company following the launch of Wegovy in 2021 - issued a profit warning and named a company veteran as new CEO. On Friday, the U.S. Food and Drug Administration granted accelerated approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1 class therapy cleared for the progressive liver condition that affects around 5% of adults in the United States. Rival Eli Lilly has published encouraging MASH data in a mid-stage trial with tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound. "It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market," said Nordnet analyst Per Hansen. Novo has also applied this year for approval in Europe and Japan. Its shares have lost more than two-thirds of their value since June last year, amid concerns that the Danish drugmaker is losing ground in the obesity drug race it started to rival Eli Lilly and "compounded" copycat drugs. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
By Jacob Gronholt-Pedersen COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks. Novo's shares rose as much as 5% at opening and were trading 3.5% higher by 0711 GMT. Three weeks ago, investors wiped $70 billion off its market value, after Novo - which became Europe's most valuable listed company following the launch of Wegovy in 2021 - issued a profit warning and named a company veteran as new CEO. On Friday, the U.S. Food and Drug Administration granted accelerated approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1 class therapy cleared for the progressive liver condition that affects around 5% of adults in the United States. Rival Eli Lilly has published encouraging MASH data in a mid-stage trial with tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound. "It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market," said Nordnet analyst Per Hansen. Novo has also applied this year for approval in Europe and Japan. Its shares have lost more than two-thirds of their value since June last year, amid concerns that the Danish drugmaker is losing ground in the obesity drug race it started to rival Eli Lilly and "compounded" copycat drugs. Sign in to access your portfolio
Medscape
2 hours ago
- Medscape
FDA Warns of Future Action on Animal-Derived Thyroid Drugs
The top US regulator of medicines this week said he wants to officially approve an animal-derived thyroid drug, seemingly addressing concerns sparked by a press release from his own agency. On August 6, the FDA sent letters to manufacturers, importers, and distributors of animal-derived thyroid medications, stating that the agency 'intends to take action against marketed unapproved animal-derived thyroid (ADT) products (sometimes described as desiccated thyroid extract [DTE] products).' 'Due to their complex biological origin, these medications contain many compounds that are uncharacterized for safety and effectiveness,' the FDA said, noting that it could take as long as '12 months to safely transition patients to an FDA-approved thyroid hormone replacement product.' 'FDA is not taking immediate action against manufacturers who make unapproved animal-derived thyroid medication to give patients time to transition to an FDA-approved medication to treat their hypothyroidism,' the agency said. Following this announcement, in an August 13 post on his verified account on X, FDA Commissioner Marty Makary wrote that his agency 'is committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials' and 'will in the meantime ensure access for all Americans,' without specifying what kind of thyroid medications would be available. The X post came after considerable social media backlash to the FDA's plans to shift patients toward synthetic thyroid medications and away from animal-derived versions. FDA-approved laboratory-made, or synthetic, thyroid medications currently dominate the US market. About 22 million people received prescriptions for levothyroxine through outpatient retail pharmacies in 2024 compared to an estimated 1.5 million patients who received prescriptions for animal-derived versions, the FDA said. Marketed under names such as Armour Thyroid, NP Thyroid, Nature-Thyroid, and Natural Thyroid, these medications are produced from dried, ground animal thyroid glands, usually those of pigs. Complex History The FDA has had a long and challenging history with regulating thyroid medicines. These drugs were first sold in the US well before federal laws gave the FDA the regulatory powers it now has, Antonio Bianco, MD, PhD, of the University of Texas Medical Branch, Galveston, Texas, and former president of the American Thyroid Association, told Medscape Medical News . 'Because they existed before the FDA, their regulatory pathway is really complicated,' Bianco said. In 1965, four of every five prescriptions for thyroid hormone were for natural thyroid preparations, as pharmacologic authorities confirmed that these were highly effective, well-absorbed, and produced clinically predictable outcomes, wrote Roselyn Cristelle Mateo-Collado, MD, of Rush University, Chicago, and James V. Hennessey, MD, of Harvard Medical School, Boston, in a 2019 review in Endocrine . But reports of patients not responding to desiccated thyroid triggered concerns about inconsistencies in the potency of these tablets, they added. Over time, a newer synthetic version, levothyroxine, became more widely used, even with concerns arising as well about inconsistent potency. Between 1987 and 1994, the FDA received 58 adverse experience reports associated with the potency of orally administered levothyroxine products. In 1997, the FDA mandated that any company wishing to market levothyroxine must first secure agency approval. In 2002, Abbott Laboratories received approval to keep selling its levothyroxine drug, Synthroid, which had been on the market for more than 40 years and was being taken by about 8 million people in the US, Abbott said at the time. In 2013, Abbott spun off its drug business as AbbVie. AbbVie now markets both Synthroid and Armour Thyroid, a desiccated thyroid drug. What's Next? In his X post, the FDA chief Makary did not mention any specific studies that he expects to lead to approval of a desiccated thyroid drug. AbbVie is sponsoring a phase 2/3 study examining the safety of its Armour Thyroid against the synthetic thyroid medicine, according to the website. AbbVie declined to comment on this story. Other companies also are working on research studies for their animal-derived thyroid drugs, so the FDA's August 7 announcement came as an unwelcome surprise for many people, Bianco said. Makary's X post this week likely was meant to respond to pushback from supporters of the animal-derived drugs, he added, noting that the commissioner's tone may signal that the agency is 'correcting course' and minimizing the impact of the agency's announcement. 'The manufacturers are working very hard' on large-scale trials, Bianco said. 'They require money and time to be done properly, and I think that's what the FDA should be stimulating.' Bianco reported being a consultant for AbbVie, Acella, Aligos, and Synthonics.
